Faron Pharmaceuticals Oy (FARN) is a leading biotechnology business based in the UK. It opened the day at 418.0001p after a previous close of 430p. During the day the price has varied from a low of 415p to a high of 450p. The latest price was 432.5p (25 minute delay). Faron Pharmaceuticals Oy is listed on the London Stock Exchange (LSE) and employs 24 staff. All prices are listed in pence sterling.
Since the stock market crash in March caused by coronavirus, Faron Pharmaceuticals Oy's share price has had significant positive movement.
Its last market close was 350p, which is 19.29% up on its pre-crash value of 282.5p and 71.70% up on the lowest point reached during the March crash when the shares fell as low as 203.8422p.
If you had bought £1,000 worth of Faron Pharmaceuticals Oy shares at the start of February 2020, those shares would have been worth £2,043.95 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth £1,538.46.
|52-week range||130p - 530p|
|50-day moving average||415.3857p|
|200-day moving average||388.5922p|
|Wall St. target price||1.35p|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||-109.5p|
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
|1 week (2020-10-20)||28.34%|
|1 month (2020-09-28)||4.22%|
|3 months (2020-07-27)||-4.95%|
|6 months (2020-04-27)||17.69%|
|1 year (2019-10-25)||200.35%|
|2 years (2018-10-26)||421.08%|
|3 years (2017-10-27)||-48.20%|
|Gross profit TTM||£0|
|Return on assets TTM||-89.37%|
|Return on equity TTM||-511.18%|
|Market capitalisation||£157.8 million|
TTM: trailing 12 months
We're not expecting Faron Pharmaceuticals Oy to pay a dividend over the next 12 months. However, you can browse other dividend-paying shares in our guide.
Over the last 12 months, Faron Pharmaceuticals Oy's shares have ranged in value from as little as 130p up to 530p. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (LSE average) beta is 1, while Faron Pharmaceuticals Oy's is -0.1377. This would suggest that Faron Pharmaceuticals Oy's shares have been inversely-correlated to the average (for this exchange) – so when the broader market trended up or down, Faron Pharmaceuticals Oy has bucked the trend.
Faron Pharmaceuticals Oy operates as a clinical stage drug discovery and development company in Finland. It has a pipeline of drug development projects focusing on acute trauma, cancer growth and spread, and inflammatory diseases. The company's lead product candidates are Traumakine, a recombinant human IFN beta-1a, which is in Phase III clinical trial for the treatment of acute respiratory distress syndrome (ARDS); and Clevegen, an immunotherapy candidate, designed to prevent tumor growth and metastasis that targets the tumor immune suppressor molecule; and D-ARDS, a diagnostic tool to estimate ARDS severity and to follow ARDS outcome. Faron Pharmaceuticals Oy has a collaboration with MediCity unit of Turku University Medical School. The company was founded in 2003 and is headquartered in Turku, Finland.
Everything we know about the Virpax Pharmaceuticals IPO, plus information on how to buy it.
Everything we know about the Vivos Therapeutics IPO, plus information on how to buy it.
Everything we know about the Kiromic Biopharma IPO, plus information on how to buy it.
Everything we know about the Codiak BioSciences IPO, plus information on how to buy it.
Everything we know about the Triller IPO, plus information on how to buy it.
Everything we know about the Eastern Bank IPO, plus information on how to buy it.
Everything we know about the Wish IPO, plus information on how to buy it.
Everything we know about the MINISO Group Holding Limited IPO, plus information on how to buy it.
Everything we know about the Playboy IPO, plus information on how to buy it.
Everything we know about the iHuman IPO, plus information on how to buy it.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.